FET-PET/MRI
Phase 1Small molecule
FET-PET/MRI is one of 33 small molecule programs targeting Adenoma. It is currently in Phase 1.
1
Indications
2
Total Trials
1
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
45 competitors in Adenoma
#DrugCompanyPhaseTrials
1Dostinex
PfizerApproved
Orilissa
AbbVieApproved
Nolvadex
AstraZenecaApproved
Octreotide Lar
NovartisApproved
Duragesic
CCephalon
Approved
Lifyorli (copackaged)
CCorcept Therapeutics
Phase 3
Celebrex
PPhiladelphia Eye Associates
Phase 3
Lanreotide PRF
IpsenPhase 3
Olumiant
Eli LillyPhase 2
Selenium
SSWOG Cancer Research Network
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for FET-PET/MRI. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details